Overview A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) Status: Completed Trial end date: 2004-12-01 Target enrollment: Participant gender: Summary To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit. Phase: Phase 3 Details Lead Sponsor: Japan Clinical Oncology GroupCollaborator: Ministry of Health, Labour and Welfare, JapanTreatments: Lenograstim